# Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy

> **NCT02072408** · PHASE4 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 46 (actual)

## Conditions studied

- Polypoidal Choroidal Vasculopathy Without Active Polyp

## Interventions

- **DRUG:** aflibercept

## Key facts

- **NCT ID:** NCT02072408
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2017-11-02
- **Final completion:** 2017-11-02
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2018-09-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072408, "Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT02072408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*